Skip to main navigation
About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisors
Technology & Pipeline
Pipeline
Vascular Targeting System (VTS)
Ofra Vec
Monocyte Targeting Technology (MTT)
VB-601
Patients & Caregivers
Clinical Trials
Resources
Expanded Access Program
Investor Relations
IR Homepage
Press Releases
Events and Presentations
Upcoming Events
Archived Events
Presentations
Stock Information
Stock Quote/Interactive Chart
Stock prices historical lookup
Stock Calculator
Analyst Coverage
SEC Filings
Corporate Governance
Highlights
Leadership Team
Board of Directors
Committee Composition
Investor FAQ & Contacts
FAQs
Contacts
ESG Policy
Contact Us
Menu
Search
Search
About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisors
Technology & Pipeline
Pipeline
Vascular Targeting System (VTS)
Ofra Vec
Monocyte Targeting Technology (MTT)
VB-601
Patients & Caregivers
Clinical Trials
Resources
Expanded Access Program
Investor Relations
IR Homepage
Press Releases
Events and Presentations
Upcoming Events
Archived Events
Presentations
Stock Information
Stock Quote/Interactive Chart
Stock prices historical lookup
Stock Calculator
Analyst Coverage
SEC Filings
Corporate Governance
Highlights
Leadership Team
Board of Directors
Committee Composition
Investor FAQ & Contacts
FAQs
Contacts
ESG Policy
Contact Us
Breaking Boundaries
Engineering the Future Of
Targeted Medicines
Latest News
VBL Therapeutics Announces Workforce Reduction
Read More
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
Read More
Copyright © 2022 VBL Therapeutics.
Terms and Conditions
.
Privacy Policy
.
Investor Calendar
BIO CEO & Investor Conference Presentation Details
February 13, 2017
from 9:30 AM to 9:30 AM EST
Investor Tools
Print Page
RSS
Email Alerts
Contact Us